Important note: Information in this article was accurate in July 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 7, July 2005
Polly Clayden, HIV i-Base
Three studies from Johnson et al, Flys et al and Eshleman et al, looking at nevirapine resistance and persistence which we covered in our HTB CROI report are published in the Journal of Infectious Diseases. [1, 2, 3]
These are accompanied by an editorial commentary from Scott Hammer entitled (and in danger of becoming the new nevirapine resistance catch phrase): “The more you look the more you find”, in which he provides an overview of the more recent data and its implications. [4]
And in the Journal of Acquired Immune Deficiency Syndrome, Kagaayi et al report an encouragingly low rate of transmission (7.5%) and high rate of adherence to maternal (85.2%) and infant (84.8%) self administered nevirapine doses in an underserviced rural setting in Rakai, Uganda, with considerable and readily accessible community support. [5]
The authors write: “Mothers can be empowered to self-medicate themselves and their newborns and to reduce perinatal HIV infection. In circumstances where access to or utilisation of supervised delivery care is poor, as is the case in most rural areas of sub-Saharan Africa, there is an urgent need to replicate this study in a more conventional service setting.” These results are consistent with those reported in a trial setting and conflict with less efficacious results from a field setting such as those reported from Mombasa. [6]
It seems there will be an urgent need to replicate this level of success with more complex interventions in the near future.
References
| 1. | Johnson J, Li Jin-fen, Morris L et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005 Jul 1;192(1):16-23. |
| 2. | Flys T, Nissley D, Claasen CW et al. Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single dose nevirapine: HIVNET 012. J Infect Dis. 2005 Jul 1;192(1):24-99. |
| 3. | Eshleman SH, Hoover D, Chen S et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single dose nevirapine. J Infect Dis. 2005 Jul 1;192(1):30-6. |
| 4. | Hammer SM. The more you look, the more you find. J Infect Dis. 2005 Jul 1;192(1):1-3. |
| 5. | Kagaayi J, Dreyfuss ML, Kigozi G et al. Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda. J Acquir Immune Defic Syndr. 2005 May 1;39(1):121-4. |
| 6. | Quaghebeur A, Mutunga L, Mwanyumba F, et al. Low efficacy of nevirapine (HIVNET 012) in preventing HIV-1 transmission in a real life situation. AIDS. 2004 Sep 3;18(13):1854-6. |
050710
IB050607-14
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
